.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median consequence of 11 months, individuals along with metastatic stomach cysts who acquired biomarker-matched therapies based on distributing growth DNA profiling presented a higher scientific benefit than those acquiring incomparable therapy.